Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ticker | Board | News | Price | Change | Chg% | Added | ||||
---|---|---|---|---|---|---|---|---|---|---|
AEZS | AEterna Zentaris Inc. | 2.15 | 0.06 | 2.87% | 04/05/2016 | |||||
My AEZS Pitch: AEZS may generate $27/share annual revenue. In the US alone Zoptrex could generate $300 m annually. Macrilen in the US alone could generate upto $50m in the US alone.That's 350million/12.9 million outstanding shares = 27dollar/share as revenue for 1 year EXCLUDING Europe and China + their pipeline.
|
||||||||||
ADXS | Ayala Pharmaceuticals Inc | 0.5305 | -0.1126 | -17.51% | 03/28/2014 | |||||
BMNM | Bimini Capital Management, Inc. | 0.6501 | -0.1999 | -23.52% | 02/25/2014 | |||||
GCM | Gran Colombia Gold Corporation - | 0 | 0 | 0.00% | 08/02/2016 | |||||
My GCM Pitch: Junior Gold Miner.Made net profit last quarter for the first time. Profitable when the gold price had an average of 1190 and in the know they have produced more gold quarter after quarter.Book value per share: CAD 1.44 THAT IS A 10 bagger! https://ca.finance.yahoo.com/q/ks?s=GCM.TO
|
||||||||||
LXRX | Lexicon Pharmaceuticals Inc | 1.69 | 0.04 | 2.42% | 03/19/2014 | |||||
MSTX | Mast Therapeutics, Inc. | 05/13/2016 | ||||||||
My MSTX Pitch: I believe hydroxyurea (in 60% of the patients), lower mean age of population (14y.o.), the quality of the study sites and the largest study ever will take care they meet their endpoints with the primary endpoint having a p value below .05
|